Login to Your Account

Diurnal gets $10M for phase III study of Chronocort in CAH

By Cormac Sheridan
Staff Writers

Wednesday, August 6, 2014
Diurnal Ltd. is raising up to £6 million (US$10.1 million) to complete phase III development of Chronocort, a modified-release formulation of hydrocortisone, for treating congenital adrenal hyperplasia (CAH).

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription